Bank of America Securities: Boosts Kangji Medical's (06185) target price to HKD 56, reiterates "buy" rating.

According to the Wise Wealth Financial APP, Bank of America Securities released a research report stating that Kangxino Bio (06185) had a 31% year-on-year increase in revenue in the first half of the year, with net losses narrowing. Due to the growth in sales of MCV4 Menhycia, revenue from meningococcal vaccines in the first half of the year increased by 38.4% year-on-year. Benefiting from the rise in sales of high-profit vaccines and the increase in production capacity utilization, the gross profit margin of vaccine products in the first half of the year increased to 79.3%, a year-on-year increase of 12 percentage points. Bank of America Securities raised its earnings per share forecast for 2028 to 2034 by 7% to 11%, considering its leading research and development capabilities in various technological pathways and strong overseas expansion capabilities. They reiterated their "buy" rating on Kangxino with a target price raised from HK$43 to HK$56.